Biotech Values

[DewDiligence]

Re: GTCB webcast

>First time I have heard Cox be so specific regarding a partner and offer a time for the deal to be completed.<

Today’s webcast language on partnering was unchanged from prior guidance except that one prospective pan-European partner (singular) was emphasized as opposed to prospective partners in general.

I would not read a lot into this nuance. Moreover, I’ve never been especially concerned about GTC’s ability to find a development and commercialization partner for ATryn. The bottleneck, such as it is, is on the regulatory front.